ABOUT

Normin Health 
 

Normin Health was founded by Dr. Wendong Chen in 2012. Since then, Normin Health started the first observational study using hospital data to assess treatment outcomes and hospital costs associated with first-line and second-line chemotherapies in patients with non-squamous non-small cell lung cancer. With the huge success of this very first project, Normin Health has built up a highly specialized team to conduct real-world studies and develop health economic models to meet the evidence needs of developing market access strategies, supporting reimbursement submissions, and supporting commercial promotions. Normin Health has provided services to many international pharmaceutical and medical devices companies. These companies include Eli Lilly, Xian Janssen, BMS, Novartis Oncology, Gilead, Celgene, J &J, and BD. Normin Health has been highly recognized by these clients for professionalism, innovation, and quality. Normin Health is also actively developing new business to better meet market access needs. These new businesses include the development of mobile phone APP communication tool for better communications of the clinical and economic values of medical products and the development of patient follow-up mobile phone APP to fill the current real-world data gaps. 

 
Founder of Normin Health 
wdchen_edited.jpg
Wendong Chen, MD, PhD

wendong.chen@normin.ca 

Dr. Wendong Chen is the founder of Normin Health. Dr. Chen received his MD from Beijing Medical Univesity (now is the medical school of Peking University) in Beijing, China and his Ph.D. in health outcomes and economic evaluation from the department of health policy, management, and evaluation at the University of Toronto. Dr. Wendong Chen also worked on evidence-based medicine for three years at the University of Copenhagen. Dr. Wendong Chen has authored over 40 publications in health outcomes and economic research related to cancers (lung cancer, breast cancer, prostate cancer, multiple myeloma), chronic diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, chronic viral hepatitis), and medical devices (hemostatic agents, vena cave filters, and staplers). The academic affiliations of Dr. Wendong Chen include Toronto Health Economics and Technology Assessment Collaborative at the University of Toronto in Canada and the Second Xiangya Hospital of Central South University in China. 

  1. Cao, Yang, Fang Xiong, Xiaozhe Xia, Pengjuan Gu, Qinghong Wang, Aiping Wu, Huan Zhan, Wendong Chen, and Zhaoxin Qian. "Economic impact of powered stapler in video-assisted thoracic surgery lobectomy for lung Cancer in a Chinese tertiary hospital: a cost-minimization analysis." Health Economics Review 2022; 12(1): 1-13.

  2. Yang Gao, Fang Xiong, Xiaozhe Xia, Pengjuan Gu, Qinghong Wang, Aiping Wu, Huan Zhan, Wendong Chen, and Zhaoxin Qian. Clinical outcomes of powered and manual staplers in video-assisted thoracic surgery lobectomy for lung cancer. Journal of Comparative Effectiveness Research 2021; 10(13):1011-9.

  3. Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474.

  4.  Chen H, Shi J, Pan Y, et al. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China[J]. Advances in Therapy, 2020, 37(1): 431-449.

  5. Zhong Q, Tan Y, Chen W, et al. Disease burden of schizophrenia patients visiting a Chinese regional mental health centre. J Comp Eff Res. 2020;9(7):469-481.

  6. Lu J, Chen W. Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China. Journal of comparative effectiveness research. 2019 Jun 24.

  7. Zhaoxin Qian, Yinhuai Wang, Zhengyan Tang, Da Ren, Zhao Wang, Wendong Chen & Zhihong Li. Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings. Journal of medical economics 2019. 22(8):728-735.

  8. Ke X, Du Y, Zheng Y, Su L, Chen Y, Zhang Y, Chen K, Cheng Y, Chen W. Risk factors for the difficulties in general activities across the day in Chinese children and adolescents with attention-deficit/hyperactivity disorder. Neuropsychiatric disease and treatment. 2019;15:157.

  9. Yu Z, Liu Y, Cui Y, Ma R, Zhan H, Chen W, Liu H. Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China. Journal of comparative effectiveness research. 2019 Mar 29;8(7):487-95.

  10. Wu Y, Wu Y, Gangoli G, Bourcet A, Danker III W, Gong Q, Zhan H, Chen W, Wang Z. Using flowable gelatin in anterior cervical spine surgery in real-world practice: a retrospective cohort study. Journal of comparative effectiveness research. 2019 Jan 24;8(5):317-26.

  11. Yan F, Yang Y, Huang Q, Chen Y, Jia P, Chen W, Ma X. Cost-effectiveness of a free drug program for schizophrenia in Beijing, China. International Journal of Social Psychiatry. 2019 Feb;65(1):28-37.

  12.  Bing Wu, Kai Song, Qianyi Gong, Huan Zhan, Wendong Chen & Zheng Wang. Perioperative outcomes and hospital costs associated with flowable gelatin hemostatic matrix for lumbar surgeries in the real-world hospital setting, Journal of Medical Economics 2019, 22(9):917-923

  13. Du Y, Zheng Y, Ke X, Su L, Coghill D, Chen Y, Zhang Y, Yuan Z, Cheng Y, Chen W. Validity and reliability of the Dundee difficult times of the day scale in Chinese children and adolescents with attention-deficit/hyperactivity disorder. Journal of comparative effectiveness research. 2018 Nov 23;8(1):33-44.

  14. Li J, Liu Q, Chen Y, Gao S, Zhang J, Yang Y, Chen W. Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis. Journal of medical economics. 2017 Jan 2;20(1):91-7.

  15. Li J, Wen Z, Cai A, Tian F, Zhang L, Luo X, Deng L, He J, Yang Y, Chen W. Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. Journal of comparative effectiveness research. 2017 May;6(3):205-18.

  16. Chen J, Wu S, Hu C, Yang Y, Rajan N, Chen Y, Yang C, Li J, Chen W. Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study. ClinicoEconomics and outcomes research: CEOR. 2016;8:97.

  17. Chen W, Yang Y, Chen Y, Du F, Zhan H. Cost-effectiveness of bortezomib for multiple myeloma: a systematic review. ClinicoEconomics and outcomes research: CEOR. 2016;8:137.

  18. Li X, Wang Y, Wang Y, Chen J, Wu S, Hu C, Yang Y, Rajan N, Papadimitropoulos M, Chen Y, Peng T. Supportive care costs associated with second-line chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. Drugs-real world outcomes. 2015 Mar 1;2(1):87-97.

  19. Wang Y, Chen J, Wu S, Hu C, Li X, Wang Y, Yang Y, Rajan N, Chen Y, Chen Y, Luo Z. Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study. BMC Cancer. 2014 Dec;14(1):940.

  20. Hu C, Wang Y, Chen J, Wu S, Li X, Wang Y, Yang Y, Rajan N, Papadimitropoulos M, Xiao Q, Zhan H. Tumor response and clinical toxicity associated with second‐line chemotherapy regimens for advanced non‐squamous non‐small cell lung cancer: A retrospective cohort study. Thoracic Cancer. 2014 Sep;5(5):365-76.

  21. Song Y, Yang Y, Chen W, Liu W, Wang K, Li X, Wang K, Papadimitropoulos M, Montgomery W. Clinical response and hospital costs associated with the empirical use of vancomycin and linezolid for hospital-acquired pneumonia in a Chinese tertiary care hospital: a retrospective cohort study. ClinicoEconomics and outcomes research: CEOR. 2014;6:451.

Publications of Normin Health 
Need more details? Contact us

We are here to assist. Contact us by phone, email or via our Social Media channels.